629 related articles for article (PubMed ID: 26791934)
21. Probing the mechanisms of drug release from amorphous solid dispersions in medium-soluble and medium-insoluble carriers.
Sun DD; Lee PI
J Control Release; 2015 Aug; 211():85-93. PubMed ID: 26054795
[TBL] [Abstract][Full Text] [Related]
22. Variation in Supersaturation and Phase Behavior of Ezetimibe Amorphous Solid Dispersions upon Dissolution in Different Biorelevant Media.
Elkhabaz A; Sarkar S; Dinh JK; Simpson GJ; Taylor LS
Mol Pharm; 2018 Jan; 15(1):193-206. PubMed ID: 29161509
[TBL] [Abstract][Full Text] [Related]
23. Impact of polymer type on bioperformance and physical stability of hot melt extruded formulations of a poorly water soluble drug.
Mitra A; Li L; Marsac P; Marks B; Liu Z; Brown C
Int J Pharm; 2016 May; 505(1-2):107-14. PubMed ID: 27012984
[TBL] [Abstract][Full Text] [Related]
24. Formulation of fast disintegrating tablets of ternary solid dispersions consisting of TPGS 1000 and HPMC 2910 or PVPVA 64 to improve the dissolution of the anti-HIV drug UC 781.
Goddeeris C; Willems T; Van den Mooter G
Eur J Pharm Sci; 2008 Aug; 34(4-5):293-302. PubMed ID: 18602800
[TBL] [Abstract][Full Text] [Related]
25. Impact of Hydroxypropyl Methylcellulose Acetate Succinate Critical Aggregation Concentration on Celecoxib Supersaturation.
Bristol AN; Lamm MS; Li Y
Mol Pharm; 2021 Dec; 18(12):4299-4309. PubMed ID: 34738825
[TBL] [Abstract][Full Text] [Related]
26. Drug-polymer-water interaction and its implication for the dissolution performance of amorphous solid dispersions.
Chen Y; Liu C; Chen Z; Su C; Hageman M; Hussain M; Haskell R; Stefanski K; Qian F
Mol Pharm; 2015 Feb; 12(2):576-89. PubMed ID: 25535667
[TBL] [Abstract][Full Text] [Related]
27. Insights into the Dissolution Mechanism of Ritonavir-Copovidone Amorphous Solid Dispersions: Importance of Congruent Release for Enhanced Performance.
Indulkar AS; Lou X; Zhang GGZ; Taylor LS
Mol Pharm; 2019 Mar; 16(3):1327-1339. PubMed ID: 30669846
[TBL] [Abstract][Full Text] [Related]
28. Mid-infrared spectroscopy as a polymer selection tool for formulating amorphous solid dispersions.
Wegiel LA; Mauer LJ; Edgar KJ; Taylor LS
J Pharm Pharmacol; 2014 Feb; 66(2):244-55. PubMed ID: 24433425
[TBL] [Abstract][Full Text] [Related]
29. A comparative study of the effect of spray drying and hot-melt extrusion on the properties of amorphous solid dispersions containing felodipine.
Mahmah O; Tabbakh R; Kelly A; Paradkar A
J Pharm Pharmacol; 2014 Feb; 66(2):275-84. PubMed ID: 24433426
[TBL] [Abstract][Full Text] [Related]
30. Characterization of ternary solid dispersions of itraconazole, PEG 6000, and HPMC 2910 E5.
Janssens S; de Armas HN; Roberts CJ; Van den Mooter G
J Pharm Sci; 2008 Jun; 97(6):2110-20. PubMed ID: 17847067
[TBL] [Abstract][Full Text] [Related]
31. In vitro characterization of a novel polymeric system for preparation of amorphous solid drug dispersions.
Mahmoudi ZN; Upadhye SB; Ferrizzi D; Rajabi-Siahboomi AR
AAPS J; 2014 Jul; 16(4):685-97. PubMed ID: 24789531
[TBL] [Abstract][Full Text] [Related]
32. Dissolution and precipitation behavior of amorphous solid dispersions.
Alonzo DE; Gao Y; Zhou D; Mo H; Zhang GGZ; Taylor LS
J Pharm Sci; 2011 Aug; 100(8):3316-3331. PubMed ID: 21607951
[TBL] [Abstract][Full Text] [Related]
33. Drug Release and Nanodroplet Formation from Amorphous Solid Dispersions: Insight into the Roles of Drug Physicochemical Properties and Polymer Selection.
Yang R; Mann AKP; Van Duong T; Ormes JD; Okoh GA; Hermans A; Taylor LS
Mol Pharm; 2021 May; 18(5):2066-2081. PubMed ID: 33784104
[TBL] [Abstract][Full Text] [Related]
34. Hot-melt extruded hydroxypropyl methylcellulose acetate succinate based amorphous solid dispersions: Impact of polymeric combinations on supersaturation kinetics and dissolution performance.
Butreddy A; Sarabu S; Almutairi M; Ajjarapu S; Kolimi P; Bandari S; Repka MA
Int J Pharm; 2022 Mar; 615():121471. PubMed ID: 35041915
[TBL] [Abstract][Full Text] [Related]
35. Microstructure Formation for Improved Dissolution Performance of Lopinavir Amorphous Solid Dispersions.
Li N; Taylor LS
Mol Pharm; 2019 Apr; 16(4):1751-1765. PubMed ID: 30811205
[TBL] [Abstract][Full Text] [Related]
36. Phase Behavior of Ritonavir Amorphous Solid Dispersions during Hydration and Dissolution.
Purohit HS; Taylor LS
Pharm Res; 2017 Dec; 34(12):2842-2861. PubMed ID: 28956218
[TBL] [Abstract][Full Text] [Related]
37. Solubility advantage of amorphous pharmaceuticals, part 3: Is maximum solubility advantage experimentally attainable and sustainable?
Murdande SB; Pikal MJ; Shanker RM; Bogner RH
J Pharm Sci; 2011 Oct; 100(10):4349-56. PubMed ID: 21630280
[TBL] [Abstract][Full Text] [Related]
38. Aggregation of Hydroxypropyl Methylcellulose Acetate Succinate under Its Dissolving pH and the Impact on Drug Supersaturation.
Wang S; Liu C; Chen Y; Zhu AD; Qian F
Mol Pharm; 2018 Oct; 15(10):4643-4653. PubMed ID: 30130968
[TBL] [Abstract][Full Text] [Related]
39. Investigating the Correlation between Miscibility and Physical Stability of Amorphous Solid Dispersions Using Fluorescence-Based Techniques.
Tian B; Tang X; Taylor LS
Mol Pharm; 2016 Nov; 13(11):3988-4000. PubMed ID: 27700109
[TBL] [Abstract][Full Text] [Related]
40. Influence of Particle Size and Drug Load on Amorphous Solid Dispersions Containing pH-Dependent Soluble Polymers and the Weak Base Ketoconazole.
Monschke M; Kayser K; Wagner KG
AAPS PharmSciTech; 2021 Jan; 22(1):44. PubMed ID: 33438107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
